bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meet...
December 02 2019 - 7:30AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the
company will host a live webcast on December 9, 2019 at 8:00 p.m.
ET to review clinical data presented at the 61st American Society
of Hematology Annual Meeting and Exposition.
Investors may listen to the call by dialing (844) 825-4408 from
locations in the United States or +1 (315) 625-3227 from outside
the United States. Please refer to conference ID number
3052538.
To access the live webcast of bluebird bio’s presentation,
please visit the “Events & Presentations” page within the
Investors & Media section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcast will be
available on the bluebird bio website for 90 days following the
event.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
Cambridge, Mass., headquarters, we’re developing gene therapies for
severe genetic diseases and cancer, with the goal that people
facing potentially fatal conditions with limited treatment options
can live their lives fully. Beyond our labs, we’re working to
positively disrupt the healthcare system to create access,
transparency and education so that gene therapy can become
available to all those who can benefit.
bluebird bio is a human company powered by human stories. We’re
putting our care and expertise to work across a spectrum of
disorders including cerebral adrenoleukodystrophy, sickle cell
disease, β-thalassemia and multiple myeloma, using three gene
therapy technologies: gene addition, cell therapy and
(megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham,
N.C.; and Zug, Switzerland. For more information, visit
bluebirdbio.com.
Follow bluebird bio on social media: @bluebirdbio, LinkedIn,
Instagram and YouTube.
ZYNTEGLO, LentiGlobin, and bluebird bio are trademarks of
bluebird bio, Inc.
The full common name for ZYNTEGLO: A genetically modified
autologous CD34+ cell enriched population that contains
hematopoietic stem cells transduced with lentiviral vector encoding
the βA-T87Q-globin gene.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the advancement of, and anticipated
development and commercialization plans for, the Company’s product
candidates. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks that the
preliminary positive efficacy and safety results from our prior and
ongoing clinical trials of our product candidates will not continue
or be repeated in our ongoing or planned clinical trials; risks
that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory
submissions or to support marketing approval in the U.S. and EU;
and the risk that our product candidates will not be successfully
developed, approved or commercialized. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in our most recent Form 10-Q as well as discussions of
potential risks, uncertainties and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191202005273/en/
Investors: Elizabeth Pingpank, (617) 914-8736
epingpank@bluebirdbio.com
or
Media: Jenn Snyder, (617) 448-0281 jsnyder@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Aug 2024 to Sep 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Sep 2023 to Sep 2024